Johnson and Johnson acquired Momenta Pharmaceuticals, aims to strength immunology profile

Gilead submitted NDA for Veklury to treat COVID-19 in the US

FDA approved Genentech’s Evrysdi for Spinal Muscular Atrophy

NOVARTIS COSENTYX APPROVED IN EUROPE FOR PAEDIATRIC PSORIASIS

GSK’s first anti-BCMA therapy Blenrep was approved in the US

Gilead’s CAR-T cell therapy approved for Relapsed or Refractory Mantle Cell Lymphoma

The US FDA approved Janssen’s psoriasis blockbuster for Psoriatic Arthritis

US FDA approved Rukobia (fostemsavir) for HIV patients who have limited treatment options

JANSSEN STOPPED PHASE 3 TRIAL OF ITS BLOCKBUSTER

US FDA approved Epizyme’s Tazverik for Relapsed/Refractory Follicular Lymphoma

Eli Lilly Lyumjev secures the US FDA approval for type-1 and type-2 diabetes